Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.Clonixin: Anti-inflammatory analgesic.Iothalamate Meglumine: A radiopaque medium used for urography, angiography, venography, and myelography. It is highly viscous and binds to plasma proteins.Antiprotozoal Agents: Substances that are destructive to protozoans.Organometallic Compounds: A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.Leishmania infantum: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes visceral leishmaniasis (LEISHMANIASIS, VISCERAL). Human infections are confined almost entirely to children. This parasite is commonly seen in dogs, other Canidae, and porcupines with humans considered only an accidental host. Transmission is by Phlebotomus sandflies.Leishmania guyanensis: A parasitic hemoflagellate of the subgenus Leishmania viannia that infects man and animals and causes mucocutaneous leishmaniasis (LEISHMANIASIS, MUCOCUTANEOUS). Transmission is by Lutzomyia sandflies.Leishmania braziliensis: A parasitic hemoflagellate of the subgenus Leishmania viannia that infects man and animals. It causes cutaneous (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), and mucocutaneous leishmaniasis (LEISHMANIASIS, MUCOCUTANEOUS) depending on the subspecies of this organism. The sandfly, Lutzomyia, is the vector. The Leishmania braziliensis complex includes the subspecies braziliensis and peruviana. Uta, a form of cutaneous leishmaniasis in the New World, is caused by the subspecies peruviana.Leishmania mexicana: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals including rodents. The Leishmania mexicana complex causes both cutaneous (LEISHMANIASIS, CUTANEOUS) and diffuse cutaneous leishmaniasis (LEISHMANIASIS, DIFFUSE CUTANEOUS) and includes the subspecies amazonensis, garnhami, mexicana, pifanoi, and venezuelensis. L. m. mexicana causes chiclero ulcer, a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) in the New World. The sandfly, Lutzomyia, appears to be the vector.Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.Benzethonium: Bactericidal cationic quaternary ammonium surfactant used as a topical anti-infective agent. It is an ingredient in medicaments, deodorants, mouthwashes, etc., and is used to disinfect apparatus, etc., in the food processing and pharmaceutical industries, in surgery, and also as a preservative. The compound is toxic orally as a result of neuromuscular blockade.Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.Paromomycin: An oligosaccharide antibiotic produced by various STREPTOMYCES.ThiazinesParasitic Sensitivity Tests: Tests that demonstrate the relative effectiveness of chemotherapeutic agents against specific parasites.Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.Parasite Load: Measure of the number of the PARASITES present in a host organism.Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).Diatrizoate Meglumine: A versatile contrast medium used for DIAGNOSTIC X-RAY RADIOLOGY.Cerebral Ventriculography: Radiography of the ventricular system of the brain after injection of air or other contrast medium directly into the cerebral ventricles. It is used also for x-ray computed tomography of the cerebral ventricles.Antimony Sodium Gluconate: Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.Platelet Factor 3: A phospholipid from the platelet membrane that contributes to the blood clotting cascade by forming a phospholipid-protein complex (THROMBOPLASTIN) which serves as a cofactor with FACTOR VIIA to activate FACTOR X in the extrinsic pathway of BLOOD COAGULATION.Leishmania: A genus of flagellate protozoa comprising several species that are pathogenic for humans. Organisms of this genus have an amastigote and a promastigote stage in their life cycles. As a result of enzymatic studies this single genus has been divided into two subgenera: Leishmania leishmania and Leishmania viannia. Species within the Leishmania leishmania subgenus include: L. aethiopica, L. arabica, L. donovani, L. enrietti, L. gerbilli, L. hertigi, L. infantum, L. major, L. mexicana, and L. tropica. The following species are those that compose the Leishmania viannia subgenus: L. braziliensis, L. guyanensis, L. lainsoni, L. naiffi, and L. shawi.Aminoquinolines: Quinolines substituted in any position by one or more amino groups.Leishmaniasis, Mucocutaneous: A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.Leishmania tropica: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and rodents. This taxonomic complex includes species which cause a disease called Oriental sore which is a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) of the Old World.Nicotinic Acids: 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin.ColombiaPhosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.Injections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.Horse Diseases: Diseases of domestic and wild horses of the species Equus caballus.Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.Contrast Media: Substances used to allow enhanced visualization of tissues.Societies, Pharmaceutical: Societies whose membership is limited to pharmacists.Internship, Nonmedical: Advanced programs of training to meet certain professional requirements in fields other than medicine or dentistry, e.g., pharmacology, nutrition, nursing, etc.Reference Books, Medical: Books in the field of medicine intended primarily for consultation.Pharmacists: Those persons legally qualified by education and training to engage in the practice of pharmacy.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Hospitals, AnimalAnti-Inflammatory Agents, Non-Steroidal: Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.Musculoskeletal Diseases: Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively.Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.Gadolinium: Gadolinium. An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.Biological Availability: The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Polymers: Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS).South CarolinaAlabamaBerlinMexicoMarylandRadiology: A specialty concerned with the use of x-ray and other forms of radiant energy in the diagnosis and treatment of disease.
Low resting potential and postnatal upregulation of NMDA receptors may cause Cajal-Retzius cell death. (1/478)
Using in situ patch-clamp techniques in rat telencephalic slices, we have followed resting potential (RP) properties and the functional expression of NMDA receptors in neocortical Cajal-Retzius (CR) cells from embryonic day 18 to postnatal day 13, the time around which these cells normally disappear. We find that throughout their lives CR cells have a relatively depolarized RP (approximately -50 mV), which can be made more hyperpolarized (approximately -70 mV) by stimulation of the Na/K pump with intracellular ATP. The NMDA receptors of CR cells are subjected to intense postnatal upregulation, but their similar properties (EC50, Hill number, sensitivity to antagonists, conductance, and kinetics) throughout development suggest that their subunit composition remains relatively homogeneous. The low RP of CR cells is within a range that allows for the relief of NMDA channels from Mg2+ blockade. Our findings are consistent with the hypothesis that CR cells may degenerate and die subsequent to uncontrolled overload of intracellular Ca2+ via NMDA receptor activation by ambient glutamate. In support of this hypothesis we have obtained evidence showing the protection of CR cells via in vivo blockade of NMDA receptors with dizocilpine. (+info)Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. (2/478)
Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals. (+info)Value of Western blotting in the clinical follow-up of canine leishmaniasis. (3/478)
Specific serum antibody levels in Leishmania infantum-infected dogs treated with a combination of glucantime and allopurinol were estimated by indirect immunofluorescence and Western blotting. The sensitivity of Western blot was greater than that obtained with immunofluorescence titration. In general, both diagnostic methods concurred with the post-treatment clinical status of the animals. Clinical improvement of successfully treated dogs was related to lower immunofluorescence titers and simpler and/or less reactive immunodetection patterns in Western blotting. The recognition, by infected dogs, of certain low molecular weight antigens, particularly one of approximately 26 kDa, was restricted to pretreatment samples and a single animal in relapse thus apparently constituting an active infection marker. (+info)Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin. (4/478)
Intracerebral injection of neurotensin into specific brain loci in rats produces hyperalgesia due to the release of cholecystokinin (CCK) in the spinal cord. The present purpose was to show in another species that neurotensin can antagonize the antinociceptive action of morphine through the spinal CCK mechanism in mice. Neurotensin given intracerebroventricularly (i.c.v.) at doses higher than 100 ng produced antinociception in the tail flick test. However, at lower doses between 1 pg to 25 ng, neurotensin antagonized the antinociceptive action of morphine given intrathecally (i.t.), thus demonstrating the antianalgesic activity of neurotensin. The rightward shift in the morphine dose-response curve produced by i.c.v. neurotensin was eliminated by an i.t. pretreatment with CCK8 antibody (5 microl of antiserum solution diluted 1:1000). I.t. administration of lorglumide, a CCK(A)-receptor antagonist (10-1000 ng), and PD135,158, a CCK(B)-receptor antagonist (250-500 ng), also eliminated the antianalgesic action of neurotensin. Thus, the mechanism of the antianalgesic action of neurotensin given i.c.v. involved spinal CCK. This mode of action is similar to that for the antianalgesic action of supraspinal pentobarbital which also involves spinal CCK. (+info)Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex. (5/478)
1. The previously described complex behaviour of the CCKB/gastrin receptor antagonist, L-365,260, in radioligand binding assays could be explained by a variable population of two binding sites. We have investigated whether other CCKB/gastrin receptor ligands (PD134,308, PD140,376, YM022 and JB93182) can distinguish between these sites. 2. In the mouse cortex assay, Hill slopes were not different from unity and the ligand pKI values did not differ when either [125I]-BH-CCK-8S or [3H]-PD140,376 was used as label as expected for a single site (G2). 3. In the rat cortex, where previous analysis of replicate (n=48) L-365,260 data indicated the presence of two CCKB/gastrin sites (G1 and G2), the competition data for PD134,308, PD140,376, YM022 and JB93182 could be explained by a homogeneous population of CCKB/gastrin sites because the Hill slope estimates were not significantly different from unity. However, the estimated affinity values for JB93182 and YM022 were significantly higher and that for PD134,308 was significantly lower than those obtained in the mouse cortex when the same radioligand was used. In view of our previous data obtained with L-365,260, the rat cortex data were also interpreted using a two-site model. In this analysis, SR27897 expressed approximately 9 fold, PD134,308 approximately 13 fold and PD140,376 approximately 11 fold selectivity for the G2 site. In contrast, JB93182 expressed approximately 23 fold and YM022 approximately 4 fold selectivity for the G1 site. If the two-site interpretation of the data is valid then, because of its reverse selectivity to L-365,260, JB93182 has been identified as a compound which if radiolabelled could provide a test of this receptor subdivision. (+info)Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex. (6/478)
1. We have investigated the binding of a novel radiolabelled CCKB/gastrin receptor ligand, [3H]-JB93182 (5[[[(1S)-[[(3,5-dicarboxyphenyl)amino]carbonyl]-2-phenylethyla mino]-carbonyl]-6-[[(1-adamantylmethyl) amino]carbonyl]-indole), to sites in rat cortex membranes. 2. The [3H]-JB93182 was 97% radiochemically pure as assessed by reverse-phase HPLC (RP-HPLC) and was not degraded by incubation (150 min) with rat cortex membranes. 3. Saturation analysis indicated that [3H]-JB93182 labelled a homogeneous population of receptors in rat cortex membranes (pKD=9.48+/-0.08, Bmax=3.61+/-0.65 pmol g(-1) tissue, nH=0.97+/-0.02, n=5). The pKD was not significantly different when estimated by association-dissociation analysis (pKD=9.73+/-0.11; n=10). 4. In competition studies, the low affinity of the CCKA receptor antagonists, L-364,718; SR27897 and 2-NAP, suggest that, under the assay conditions employed, [3H]-JB93182 (0.3 nM) does not label CCKA receptors in the rat cortex. 5. The affinity estimates obtained for reference CCKB/gastrin receptor antagonists were indistinguishable from one of the affinity values obtained when a two site model was used to interpret [125I]-BH-CCK8S competition curves obtained in the same tissue (Harper et al., 1999). 6. This study provides further evidence for the existence of two CCKB/gastrin sites in rat cortex. [3H]-JB93182 appears to label selectively sites previously designated as gastrin-G1 and therefore it may be a useful compound for the further discrimination and characterization of these putative receptor subtypes. (+info)Differential effects of intrathecally administered morphine and its interaction with cholecystokinin-B antagonist on thermal hyperalgesia following two models of experimental mononeuropathy in the rat. (7/478)
BACKGROUND: Cholecystokinin-B receptor activation has been reported to reduce morphine analgesia. Neuropathic pain is thought to be relatively refractory to opioids. One possible mechanisms for a reduced effect of morphine on neuropathic pain is the induction of cholecystokinin in the spinal cord by nerve injury. The authors evaluated the role of the spinal cholecystokinin-B receptor on morphine analgesia in two rat neuropathic pain models: chronic constriction injury and partial sciatic nerve injury. METHODS: A chronic constriction injury is created by placing four loosely tied ligatures around the right sciatic nerve. A partial sciatic nerve injury was created by tight ligation of one third to one half of the right sciatic nerve. All drugs were injected intrathecally 7 and 11 days after the nerve injury. The effect of the drugs was reflected in the degree of paw withdrawal latency to thermal nociceptive stimulation. The paw withdrawal latencies of injured and uninjured paws were measured 5, 15, 30, and 60 min after the drugs were injected. RESULTS: In the chronic constriction injury model, intrathecal morphine increased the paw withdrawal latencies of injured and uninjured paws. PD135158, a cholecystokinin-B receptor antagonist, potentiated the analgesic effect of morphine on injured and uninjured paws. In the partial sciatic nerve injury model, the effect of morphine on the injured paw was less potent than that on the uninjured paw, and PD135158 potentiated the morphine analgesia in the uninjured paw and had only a minor effect on the morphine analgesia in the injured paw. CONCLUSIONS: The effectiveness of morphine for thermal hyperalgesia after nerve injury depends on the type of nerve injury. The role of the cholecystokinin-B receptor in morphine analgesia in thermal hyperalgesia after nerve injury also depends on the type of nerve injury. (+info)Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells. (8/478)
BACKGROUND: Since human colon cancers often contain significant quantities of progastrin-processing intermediates, we sought to explore the possibility that the biosynthetic precursor of fully processed amidated gastrin, glycine-extended gastrin, may exert trophic effects on human colonic cancer cells. MATERIALS AND METHODS: Binding of radiolabeled glycine-extended and amidated gastrins was assessed on five human cancer cell lines: LoVo, HT 29, HCT 116, Colo 320DM, and T 84. Trophic actions of the peptides were assessed by increases in [3H]thymidine incorporation and cell number. Gastrin expression was determined by northern blot and radioimmunoassay. RESULTS: Amidated gastrin did not bind to or stimulate the growth of any of the five cell lines. In contrast, saturable binding of radiolabeled glycine-extended gastrin was seen on LoVo and HT 29 cells that was not inhibited by amidated gastrin (10(-6) M) nor by a gastrin/CCKB receptor antagonist (PD 134308). Glycine-extended gastrin induced a dose-dependent increase in [3H]thymidine uptake in LoVo (143 +/- 8% versus control at 10(-10) M) and HT 29 (151 +/- 11% versus control at 10(-10) M) cells that was not inhibited by PD 134308 or by a mitogen-activated protein (MAP) or ERK kinase (MEK) inhibitor (PD 98509). Glycine-extended gastrin did stimulate jun-kinase activity in LoVo and HT 29 cells. The two cell lines expressed the gastrin gene at low levels and secreted small amounts of amidated gastrin and glycine-extended gastrin into the media. CONCLUSIONS: Glycine-extended gastrin receptors are present on human colon cancer cells that mediate glycine-extended gastrin's trophic effects via a MEK-independent mechanism. This suggests that glycine-extended gastrin and its novel receptors may play a role in colon cancer cell growth. (+info)GadoterateIntravenousDelafloxacinAmino sugarExcipientGlucantimeInjectionTreated with meglumine antimoniateLeishmaniaTreatment of cutaneous leishmaniasisCutaneous leishmaniasis with meglumine antimoniateIothalamate meglumineSide effects of gadoterateAdministration of flunixin meglumineContains flunixin meglumine equivalentDosesAntimoniate plusAmino sugar derived from glucoseDOTAREMInjectionsIntramuscularIodineDoseEfficacyEquivalentPrecautionsMiltefosinePotent non-narcoticContrast50mgTreat leishmaniasisPlaceboAnalgesicVeterinarySystemicMedicinesAvoid
- Along with its needed effects, gadoterate meglumine may cause some unwanted effects. (drugs.com)
- Some side effects of gadoterate meglumine may occur that usually do not need medical attention. (drugs.com)
- Some side effects of gadoterate meglumine may not be reported. (drugs.com)
- MARLBOROUGH, Mass.--( BUSINESS WIRE )--GE Healthcare's innovative shatterproof polymer + PLUS PAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine). (businesswire.com)
- CLARISCAN™ (gadoterate meglumine) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine, and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. (businesswire.com)
- March 21, 2013 -- Guerbet announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. (dicardiology.com)
- For Injection: 300 mg of delafloxacin (equivalent to 433 mg delafloxacin meglumine) as a lyophilized powder in a single-dose vial for reconstitution and further dilution before intravenous infusion. (drugs.com)
- All intravenous doses of delafloxacin meglumine are administered over 60 minutes. (drugs.com)
- Discontinue delafloxacin meglumine immediately and avoid the use of fluoroquinolones, including delafloxacin meglumine, in patients who experience any of these serious adverse reactions. (drugs.com)
- Avoid delafloxacin meglumine in patients with known history of myasthenia gravis. (drugs.com)
- Delafloxacin meglumine is a fluoroquinolone anti-infective agent. (drugs.com)
- Delafloxacin meglumine is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (drugs.com)
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of delafloxacin meglumine and other antibacterial drugs, delafloxacin meglumine should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (drugs.com)
- Oral Tablets: 450 mg delafloxacin (equivalent to 649 mg delafloxacin meglumine). (drugs.com)
- Known hypersensitivity to delafloxacin meglumine or other fluoroquinolones. (drugs.com)
- Discontinue delafloxacin meglumine immediately at the first signs or symptoms of any serious adverse reaction. (drugs.com)
- In addition, avoid the use of fluoroquinolones, including delafloxacin meglumine, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones. (drugs.com)
- antiviral treatment, this review provides the verified data around the medicinal plants and related herbal substances ABT 492 meglumine (Delafloxacin meglumine) with antiviral activity, as well as applied strategies for the delivery of these herb extracts and biologically active phytochemicals. (yearofevolution.org)
- With that in mind, naturally based pharmacotherapy may be a proper alternative ABT 492 meglumine (Delafloxacin meglumine) for treating viral diseases. (yearofevolution.org)
- PI, protease inhibitor Antiviral therapeutic plant life and phytochemicals Several plants have already been used in medication since ancient moments and ABT 492 meglumine (Delafloxacin meglumine) so are known because of their strong therapeutic impact. (yearofevolution.org)
- The facility, validated by the FDA, is the only location in Europe that manufactures meglumine, an amino sugar derived from glucose. (emdgroup.com)
- Billerica, Massachusetts, January 17, 2017 - MilliporeSigma, a leading science and technology company, today announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media. (emdgroup.com)
- The facility in Spain is solely dedicated to the production of meglumine, thereby ensuring continuity of supply to customers as well as meeting increasing demand for the excipient. (emdgroup.com)
- As an excipient, meglumine interacts directly with active pharmaceutical ingredients to increase solubility. (emdgroup.com)
- We report a case of drug hypersensitivity syndrome (drug reaction with eosinophilia and systemic symptoms [DRESS]) induced by parenteral meglumine antimoniate (Glucantime) in a 40-year-old man who traveled to Bolivia and was treated for mucocutaneous leishmaniasis. (ajtmh.org)
- Pentavalent antimony compounds such as Glucantime (Meglumine antimoniate) are the first-line treatment of leishmaniasis. (termedia.pl)
- This study identified the infecting Leishmania species and evaluated the results of meglumine antimoniate (Glucantime®) therapy in a new focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. (who.int)
- 81 dogs naturally infected with Leishmania infantum in the Isle of Elba, Italy, were treated with meglumine antimoniate (Glucantime). (nih.gov)
- In this case control study, the therapeutic effect of Thio- Ben ( combination of thioxolon and benzoxonium chloride) was compared to intralesional meglumine antymoniate ( glucantime) treatment. (ac.ir)
- The leishmanicidal activity of four batches of meglumine antimoniate , produced in Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime ®-Aventis Pharma Ltda. (bvsalud.org)
- The meglumine antimoniate produced by Farmanguinhos was as effective as the reference drug, Glucantime ®-Aventis, against three species of Leishmania that are of medical importance in Brazil . (bvsalud.org)
- For Injection: 300 mg of delafloxacin (equivalent to 433 mg delafloxacin meglumine) as a lyophilized powder in a single-dose vial for reconstitution and further dilution before intravenous infusion. (drugs.com)
- DOTAREM Injection 0.5 mmol/mL contains 376.9 mg/mL of gadoterate meglumine and is available in vials and pre-filled syringes. (nih.gov)
- Some side effects of gadoterate meglumine may occur up to several days after injection. (wellspan.org)
- Ioxaglate Meglumine and Ioxaglate Sodium Injection is a sterile solution of Ioxaglic Acid in Water for Injection, prepared with the aid of Meglumine and Sodium Hydroxide. (drugfuture.com)
- Ioxaglate Meglumine and Ioxaglate Sodium Injection intended for intravascular use contains no antimicrobial agents. (drugfuture.com)
- Evaporate a volume of Injection, equivalent to about 500 mg of ioxaglate meglumine and ioxaglate sodium, to dryness, and heat the residue so obtained in a crucible: violet vapors are evolved. (drugfuture.com)
- Test solution Transfer a volume of Injection, equivalent to a total of 1.0 g of ioxaglate meglumine and ioxaglate sodium, to a 50-mL color-comparison tube, and dilute with water to 5 mL. (drugfuture.com)
- Test solution Transfer a volume of Injection, equivalent to 2 g of the total of ioxaglate meglumine and ioxaglate sodium, to a 50-mL centrifuge tube, add 25 mL of water and 15 mL of 2 N sulfuric acid, and mix thoroughly. (drugfuture.com)
- Assay for iodine Transfer an accurately measured volume of Injection, equivalent to about 5 g (total) of ioxaglate meglumine and ioxaglate sodium, to a 250-mL volumetric flask, dilute with water to volume, and mix. (drugfuture.com)
- Five cattle in each group received three doses of flunixin meglumine administered by either intravenous infusion or intramuscular injection at 24 h intervals. (elsevier.com)
- NAME: Flunixin Meglumine Injection COMPOSITION: 50ml: 2.5g flunixin as meglumine 50mg per ml. (ncpcvet.com)
- Function Antipyretic Analgesics Dosage Form Injection Animal Type Cattle, Fowl, Horse, Other Special Breeding Animals, Pets, Pig, Sheep Place of Origin Sichuan, China (Mainland) Brand Name Chengkang Model Number 10ml/vial Appearance Colorless to slight yellow transparent liquid Composition Flunixin meglumine Specification 10ml Original Sichuan, China Sample Available MOQ 1 Carton Certificate GMP OEM Accept Product Description Flunixin Meglumine Injection Main C. (jiulonghxyy.com)
- Product categories of Flunixin Meglumine , we are specialized manufacturers from China, Flunixin Injection , Flunixin Meglumine Injection suppliers/factory, wholesale high-quality products of Flunixin Meglumine Paste R & D and manufacturing, we have the perfect after-sales service and technical support. (kexingpharma.com)
- Flunixin Meglumine 10% Injection Flunixin meglumine Injection 10% is a relatively potent non-narcotic, non-steroidal analgesic with anti-inflammatory and anti-pyretic properties. (kexingpharma.com)
- Additional pediatric use information is approved for Guerbet LLC's Dotarem (gadoterate meglumine injection). (genewsroom.com)
- Analysis errors can occur in the desorbing process of ginkgo diterpene lactone meglumine injection (GDMI) by a conventional analysis method, due to several factors, such as easily crystallized samples, solvent volatility, time-consuming sample pre-processing, fixed method, and offline analysis. (bvsalud.org)
- Comparison between topical treatment with thioxolone , benzoxonium chloride tincture and intralesional injection of meglumine antymoniate on cutaneous leishmaniasis', Journal of Kerman University of Medical Sciences , 2(1), pp. 7-14. (ac.ir)
- This study was conducted to compare the effectiveness of oral zinc sulphate with intralesional meglumine antimoniate injection in the treatment of cutaneous leishmaniasis. (com.pk)
- Objective To compare the efficacy of oral zinc sulphate with intralesional meglumine antimoniate injection in patients presenting with cutaneous leishmaniasis at a tertiary care hospital. (com.pk)
- Conclusion There is no significant difference in the treatment of cutaneous leishmaniasis with oral zinc sulphate and intralesional meglumine antimoniate injection. (com.pk)
- Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. (semanticscholar.org)
- ABSTRACT In order to define the protein expressional changes related to the process of meglumine antimoniate resistance in anthroponotic cutaneous leishmaniasis (CL), we performed a comparative proteomics analysis on sensitive and resistant strains of Leishmania tropica isolated from Iranian CL patients. (who.int)
- Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions. (unil.ch)
- Comparative mitochondrial proteomics of Leishmania tropica clinical isolates resistant and sensitive to meglumine antimoniate. (bvsalud.org)
- A combination of cell fractionation , liquid chromatography - tandem mass spectrometry (LC-MS/MS), and Label-Free Quantification was used to characterize the mitochondrial protein composition of Leishmania tropica field isolates resistant and sensitive to meglumine antimoniate . (bvsalud.org)
- Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate. (ac.ir)
- A double-blind, randomized, double-masked, placebo-controlled clinical trial, including 620 patients from endemic areas for leishmaniasis in Colombia was designed to investigate whether this patch is as effective as meglumine antimoniate for the treatment of cutaneous leishmaniasis but with less adverse events. (clinicaltrials.gov)
- This study will evaluate the efficacy and safety of using pentoxifylline (PTX) as a co-adjuvant in the treatment of cutaneous leishmaniasis with meglumine antimoniate in a randomized, double-blind, controlled trial. (clinicaltrials.gov)
- A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. (com.pk)
- The purpose of this study is to determine whether adding pentoxifylline to treatment of American cutaneous leishmaniasis with meglumine antimoniate increases the rate and speed of clinical response without diminishing safety, and to identify immune correlates of the healing response. (clinicaltrials.gov)
- It is often used as an excipient in pharmaceuticals and in conjunction with iodinated compounds in contrast media such as diatrizoate meglumine, iothalamate meglumine and iodipamide meglumine. (wikipedia.org)
- The generic name of Cysto-conray Ii is iothalamate meglumine. (ndclist.com)
- Read the side effects of Gadoterate meglumine as described in the medical literature. (medindia.net)
- Some side effects of gadoterate meglumine may occur that usually do not need medical attention. (drugs.com)
- Some side effects of gadoterate meglumine may not be reported. (drugs.com)
- What are the possible side effects of gadoterate meglumine? (wellspan.org)
- The researchers conclude from their results that PO administration of flunixin meglumine is not the most effective route for mature swine when compared to IV and IM. (thepigsite.com)
- Each ml of Banamine Injectable Solution contains flunixin meglumine equivalent to 50 mg flunixin. (valleyvet.com)
- Each 30 gram syringe of Flunazine Paste contains flunixin meglumine equivalent to 1500 mg flunixin. (valleyvet.com)
- All intravenous doses of delafloxacin meglumine are administered over 60 minutes. (drugs.com)
- Flunixin Meglumine Doses: More or Less? (bloodhorse.com)
- Plasma concentrations of flunixin meglumine increased in a dose-dependent manner, but by Hour 8, there was no difference among concentrations at half-dose, 1x, and 2x doses. (bloodhorse.com)
- This is significant when treating colicking horses with smaller doses of flunixin meglumine to alleviate intestinal pain and combat endotoxemia. (bloodhorse.com)
- Since laminitis can also be a sequel to colic, owners and veterinarians should not rely on smaller-than-usual doses of flunixin meglumine to alleviate musculoskeletal pain. (bloodhorse.com)
- The MRI examinations of patients who received the recommended doses of gadoterate meglumine (0.18-0.66 ml/kg) had the best image quality, suggesting that high doses do not improve image quality. (appliedradiology.com)
- Purpose: To determine the appropriate dose of contrast medium for moving-table MR angiography (MT-MRA) from the abdominal aorta to the ankle by comparing visualization with different doses of meglumine gadopentetate (Gd-DTPA) administered in crossover fashion to normal volunteers. (elsevier.com)
- Here, we evaluated the long-term efficacy of treatment with meglumine antimoniate plus allopurinol (G1) compared to miltefosine plus allopurinol (G2) in dogs naturally infected L. infantum . (biomedcentral.com)
- The most commonly used treatments for CanL are a combination of meglumine antimoniate plus allopurinol, or miltefosine plus allopurinol. (biomedcentral.com)
- One arm will receive meglumine antimoniate and PTX and the other arm will receive meglumine antimoniate plus placebo. (clinicaltrials.gov)
- Meglumine is an amino sugar derived from glucose. (wikipedia.org)
- The facility, validated by the FDA, is the only location in Europe that manufactures meglumine, an amino sugar derived from glucose. (emdgroup.com)
- The study's objectives were to prospectively investigate the safety of gadoterate meglumine (Dotarem® or Magnescope®, Guerbet, Roissy-Charles de Gaulle, France) in observational conditions and to assess the overall incidence of nephrogenic systemic fibrosis (NSF) in patients with renal impairment. (appliedradiology.com)
- three cows received three injections of flunixin meglumine and three cows received flurbiprofen as two intravenous infusions. (bmj.com)
- A US study suggests that intramuscular administration of the pain control medication, flunixin meglumine is more effective that the oral route. (thepigsite.com)
- Researchers at Kansas State University and Iowa State University have collaborated to study the pharmacokinetics of the analgesic, flunixin meglumine, administered to mature pigs by the intravenous (IV), intramuscular (IM) and oral (PO) routes. (thepigsite.com)
- 27 patients received 60 mg/kg intramuscular meglumine antimoniate for 20 days. (ajtmh.org)
- It contains not less than 95.0 percent and not more than 105.0 percent of the labeled amounts of ioxaglate meglumine (C 24 H 21 I 6 N 5 O 8 ·C 7 H 17 NO 5 ) and iodine (I). It may contain small amounts of Edetate Calcium Disodium as a stabilizer. (drugfuture.com)
- Principal investigator Professor Philippe Soyer, MD, PhD, head of the Department of Body and Interventional Imaging and chairman of the radiology department at Hôpital Lariboisière in Paris, and co-authors reported that there was no statistically significant difference between patients with and without adverse drug reactions according to gender, age, body mass index (BMI), mean volume, or mean dose of gadoterate meglumine injected. (appliedradiology.com)
- In their study, six mature swine (121-168kg) were administered an IV, IM or PO dose of flunixin meglumine at a target dose of 2.2mg per kg in a cross-over design with a 10-day wash-out period between treatments. (thepigsite.com)
- Flunixin meglumine was administered at an actual mean dose of 2.21mg per kg (range: 2.05-2.48mg per kg) IV, IM and PO. (thepigsite.com)
- After a single oral dose of tafamidis meglumine 20 mg, approximately 59% of the dose was recovered in feces (mostly as the unchanged drug) and approximately 22% of the dose was recovered in urine (mostly as the glucuronide metabolite). (com.sv)
- Six mature swine (121-168 kg) were administered an IV, IM, or PO dose of flunixin meglumine at a target dose of 2.2 mg/kg in a cross-over design with a 10 day washout period between treatments. (beds.ac.uk)
- Flunixin meglumine was administered at an actual mean dose of 2.21 mg/kg (range: 2.05-2.48 mg/kg) IV, IM and PO. (beds.ac.uk)
- Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC 50 s of 2.7-3.2 μM. (medchemexpress.com)
- Long-term, the clinical and laboratory findings of the G1 dogs were more stable than those of the G2 dogs, thus indicating that meglumine antimoniate had better clinical efficacy than miltefosine. (biomedcentral.com)
- Oral Tablets: 450 mg delafloxacin (equivalent to 649 mg delafloxacin meglumine). (drugs.com)
- What are the warnings and precautions for Gadoterate meglumine? (medindia.net)
- Eighteen dogs with leishmaniosis were divided into the following two groups: G1 (n = 9) was treated subcutaneously with meglumine antimoniate (100 mg/kg/day/30 days) plus allopurinol (10 mg/kg/per day/30 days), while G2 (n = 9) was treated orally with miltefosine (2 mg/Kg/day/30 days) plus allopurinol (10 mg/kg/day/30 days). (biomedcentral.com)
- Clinical relapses were observed in four dogs from G2 (miltefosine/allopurinol), and just one dog from G1 (meglumine antimoniate/allopurinol). (biomedcentral.com)
- Flunixin meglumine is a potent non-narcotic, non-steroidal analgesic agent with anti-inflammatory and fever-reducing activity. (valleyvet.com)
- Gadoterate meglumine is a gadolinium based contrast agent, prescribed for visualization of brain along with with magnetic resonance imaging (MRI). (medindia.net)
- Gadoterate meglumine is a contrast agent that has magnetic properties. (wellspan.org)
- MARLBOROUGH, Mass.--( BUSINESS WIRE )--GE Healthcare's innovative shatterproof polymer + PLUS PAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine). (businesswire.com)
- CLARISCAN™ (gadoterate meglumine) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine, and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. (businesswire.com)
- A multinational study of more than 35,000 patients who had a MRI scan with gadoterate meglumine has verified that it is a well-tolerated gadolinium-based contrast agent (GBCA) and has an excellent safety profile. (appliedradiology.com)
- The meglumine salt form of diatrizoate, an organic, iodinated, radiopaque X-ray contrast medium used in diagnostic radiography. (semanticscholar.org)
- Billerica, Massachusetts, January 17, 2017 - MilliporeSigma, a leading science and technology company, today announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media. (emdgroup.com)
- 50ml: 2.5g flunixin as meglumine 50mg per ml. (ncpcvet.com)
- Each 1ml contains Flunixin Meglumine 50mg. (kexingpharma.com)
- Meglumine antimoniate is a medicine used to treat leishmaniasis. (wikipedia.org)
- During 20 days Group 1 will receive simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 will receive placebo of meglumine antimoniate and active nitric oxide patches. (clinicaltrials.gov)
- Flunixin Meglumine is a potent inhibitor of COX used as analgesic agent with anti-inflammatory and antipyretic activity. (medchemexpress.com)
- Buy 6 Banamine (Flunixin Meglumine) Veterinary (item 134RX) and save! (valleyvet.com)
- Systemic meglumine antimoniate (MA) therapy with 10-20 mg Sb5+/kg/day is the first choice of treatment. (figshare.com)
- Other drugs may affect gadoterate meglumine, including prescription and over-the-counter medicines, vitamins, and herbal products. (wellspan.org)
- What should I avoid after receiving gadoterate meglumine? (wellspan.org)